348 related articles for article (PubMed ID: 28071891)
1. Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
Han H; Valdepérez D; Jin Q; Yang B; Li Z; Wu Y; Pelaz B; Parak WJ; Ji J
ACS Nano; 2017 Feb; 11(2):1281-1291. PubMed ID: 28071891
[TBL] [Abstract][Full Text] [Related]
2. Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment.
Han H; Wang J; Chen T; Yin L; Jin Q; Ji J
J Colloid Interface Sci; 2017 Dec; 507():217-224. PubMed ID: 28800445
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Yin N; Yu H; Zhang X; Lv X
Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
[TBL] [Abstract][Full Text] [Related]
4. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
5. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
6. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial and sequential delivery of gemcitabine and oseltamivir phosphate from implantable poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell survival.
Allison Logan S; Brissenden AJ; Szewczuk MR; Neufeld RJ
Drug Des Devel Ther; 2017; 11():2239-2250. PubMed ID: 28814832
[TBL] [Abstract][Full Text] [Related]
9. Macromolecular bipill of gemcitabine and methotrexate facilitates tumor-specific dual drug therapy with higher benefit-to-risk ratio.
Das M; Jain R; Agrawal AK; Thanki K; Jain S
Bioconjug Chem; 2014 Mar; 25(3):501-9. PubMed ID: 24506698
[TBL] [Abstract][Full Text] [Related]
10. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
[TBL] [Abstract][Full Text] [Related]
11. Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy.
Wang Q; Zhu X; Wu Z; Sun T; Huang W; Wang Z; Ding X; Jiang C; Li F
J Mater Chem B; 2020 Mar; 8(12):2410-2417. PubMed ID: 32100811
[TBL] [Abstract][Full Text] [Related]
12. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
13. Fabrication of dopamine conjugated with protein @metal organic framework for targeted drug delivery: A biocompatible pH-Responsive nanocarrier for gemcitabine release on MCF‑7 human breast cancer cells.
Abd Al-Jabbar S; Atiroğlu V; Hameed RM; Guney Eskiler G; Atiroğlu A; Deveci Ozkan A; Özacar M
Bioorg Chem; 2022 Jan; 118():105467. PubMed ID: 34781115
[TBL] [Abstract][Full Text] [Related]
14. PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Ray P; Confeld M; Borowicz P; Wang T; Mallik S; Quadir M
Colloids Surf B Biointerfaces; 2019 Feb; 174():126-135. PubMed ID: 30447521
[TBL] [Abstract][Full Text] [Related]
15. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
[TBL] [Abstract][Full Text] [Related]
16. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
17. Investigations of potent biocompatible metal-organic framework for efficient encapsulation and delivery of Gemcitabine: biodistribution, pharmacokinetic and cytotoxicity study.
Kush P; Kaur M; Sharma M; Madan J; Kumar P; Deep A; Kim KH
Biomed Phys Eng Express; 2020 Feb; 6(2):025014. PubMed ID: 33438640
[TBL] [Abstract][Full Text] [Related]
18. Controlled drug release from polyelectrolyte-drug conjugate nanoparticles.
Catarata R; Azim N; Bhattacharya S; Zhai L
J Mater Chem B; 2020 Apr; 8(14):2887-2894. PubMed ID: 32191246
[TBL] [Abstract][Full Text] [Related]
19. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells.
Han NK; Shin DH; Kim JS; Weon KY; Jang CY; Kim JS
Int J Nanomedicine; 2016; 11():1413-25. PubMed ID: 27103799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
